Trial Profile
A Prospective, Randomized, Active Controlled, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Mycophenolate Mofetil (MMF) in Inducing Response and Maintaining Remission in Subjects With Lupus Nephritis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Mycophenolate mofetil (Primary) ; Azathioprine; Cyclophosphamide; Prednisolone
- Indications Lupus nephritis
- Focus Registrational; Therapeutic Use
- Acronyms ALMS
- Sponsors Roche
- 15 Nov 2023 Results assessing to compare and analyze the safety and efficacy data in propensity-matched patients from the ALMS (n=96) and AURORA 1 (n=96), presented at the ACR Convergence 2023.
- 16 Jul 2010 Status changed from recruiting to completed as reported by Roche.
- 29 Jun 2010 Further top-line results from the maintenance phase of this trial have been reported in a Vifor Pharma media release.